Cargando…

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

BACKGROUND: Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza) and exenatide (Byetta) are novel long-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hunter, Kerry, Hölscher, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352246/ https://www.ncbi.nlm.nih.gov/pubmed/22443187 http://dx.doi.org/10.1186/1471-2202-13-33

Ejemplares similares

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain
por: Mezquita-Raya, Pedro, et al.
Publicado: (2017)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
por: Feher, Michael, et al.
Publicado: (2017)

Intranasal treatment of lixisenatide attenuated emotional and olfactory symptoms via CREB-mediated adult neurogenesis in mouse depression model
por: Ren, Guoyong, et al.
Publicado: (2021)

How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases
por: Angeli, Eurydice, et al.
Publicado: (2019)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

Focused Ultrasound-Induced Neurogenesis Requires an Increase in Blood-Brain Barrier Permeability
por: Mooney, Skyler J., et al.
Publicado: (2016)

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
por: Whyte, Martin B, et al.
Publicado: (2018)

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model
por: Parthsarathy, Vadivel, et al.
Publicado: (2013)

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone
por: Trujillo, Jennifer M., et al.
Publicado: (2018)

Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL)
por: Kaneto, Hideaki, et al.
Publicado: (2022)

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
por: Barnett, Anthony H
Publicado: (2011)

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
por: Hanefeld, Markolf, et al.
Publicado: (2017)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells
por: Panagaki, Theodora, et al.
Publicado: (2017)

Improving Neurorepair in Stroke Brain Through Endogenous Neurogenesis-Enhancing Drugs
por: Wu, Kuo-Jen, et al.
Publicado: (2017)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
por: Becker, Reinhard H. A., et al.
Publicado: (2015)

Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
por: Teleanu, Raluca Ioana, et al.
Publicado: (2022)

Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS
por: Silva, Gabriel A
Publicado: (2008)

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
por: Zhao, Xu, et al.
Publicado: (2019)

Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials
por: Blonde, Lawrence, et al.
Publicado: (2016)

A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes
por: Barrientos‐Pérez, Margarita, et al.
Publicado: (2022)

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
por: Wohlfart, Paulus, et al.
Publicado: (2013)

Lost highway(s): barriers to postnatal cortical neurogenesis and implications for brain repair
por: Akhtar, Aslam Abbasi, et al.
Publicado: (2015)

Penetration of the blood-brain barrier: enhancement of drug delivery and imaging by bacterial glycopeptides
Publicado: (1995)

Drug delivery strategies to enhance the permeability of the blood–brain barrier for treatment of glioma
por: Zhang, Fang, et al.
Publicado: (2015)

Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases
por: Blethen, Kathryn E, et al.
Publicado: (2021)

Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury
por: Hakon, Jakob, et al.
Publicado: (2015)

Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies
por: Park, Tae-Eun, et al.
Publicado: (2019)

Modulation of the Blood–Brain Barrier for Drug Delivery to Brain
por: Han, Liang
Publicado: (2021)

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
por: Lind, Marcus, et al.
Publicado: (2015)

Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease
por: Banks, William A
Publicado: (2008)

Nanoparticle Strategies to Improve the Delivery of Anticancer Drugs across the Blood–Brain Barrier to Treat Brain Tumors
por: Vanbilloen, Wouter J. F., et al.
Publicado: (2023)

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis
por: Seino, Hiroaki, et al.
Publicado: (2016)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ccteb2eqjp6cudb4epm97o5mie